Holen Sie sich die Stockscreener-App
7.6999
5.91%
-0.4201
Schlusskurs vom Vortag:
$8.12
Offen:
$8.23
24-Stunden-Volumen:
77,526
Relative Volume:
0.38
Marktkapitalisierung:
$200.23M
Einnahmen:
$2.80M
Nettoeinkommen (Verlust:
$-130.30M
KGV:
-1.533
EPS:
-5.0228
Netto-Cashflow:
$-52.84M
1W Leistung:
+11.53%
1M Leistung:
+17.18%
6M Leistung:
-21.07%
1J Leistung:
-54.00%
1-Tages-Spanne:
$7.615
$8.70
1-Wochen-Bereich:
$6.55
$9.33
52-Wochen-Spanne:
$5.98
$16.79
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Firmenname
Cartesian Therapeutics Inc
Sektor
Branche
Telefon
301-348-8698
Adresse
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
7.6999 | 211.15M | 2.80M | -130.30M | -52.84M | -5.0228 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.80 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.16 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.52 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.65 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.37 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-09 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-09 | Eingeleitet | Wedbush | Outperform |
| 2024-12-19 | Eingeleitet | BTIG Research | Buy |
| 2024-08-06 | Eingeleitet | TD Cowen | Buy |
| 2024-07-02 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-04 | Eingeleitet | Oppenheimer | Outperform |
| 2024-05-24 | Eingeleitet | Mizuho | Buy |
| 2024-04-23 | Bestätigt | H.C. Wainwright | Buy |
| 2024-04-23 | Eingeleitet | Leerink Partners | Outperform |
| 2023-08-18 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | Bestätigt | Needham | Buy |
| 2022-06-06 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-01-26 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-10-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-10-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | Herabstufung | Stifel | Buy → Hold |
| 2020-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-01-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-01-21 | Eingeleitet | William Blair | Outperform |
| 2018-06-27 | Eingeleitet | Janney | Buy |
| 2017-03-30 | Bestätigt | UBS | Buy |
Alle ansehen
Cartesian Therapeutics Inc Aktie (RNAC) Neueste Nachrichten
RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch - TipRanks
Cartesian Therapeutics (NASDAQ:RNAC) Receives “Outperform” Rating from Wedbush - Defense World
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC) - The Globe and Mail
Growth Recap: Does Cartesian Therapeutics Inc have declining or rising EPS2026 Retail Activity & Stock Portfolio Risk Management - baoquankhu1.vn
Myasthenia Gravis Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC - Barchart.com
Cartesian Therapeutics (NASDAQ:RNAC) Upgraded to “Overweight” at Cantor Fitzgerald - Defense World
BTIG reiterates Buy on Cartesian Therapeutics stock, $44 target By Investing.com - Investing.com Canada
Cartesian Therapeutics Reports 2025 Financial Results, Advances Descartes-08 Cell Therapy in Autoimmune Diseases and Myasthenia Gravis Phase 3 Trial - Minichart
Mizuho reiterates Cartesian Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Cartesian Therapeutics (RNAC) Upgraded to Overweight by Cantor Fitzgerald | RNAC Stock News - GuruFocus
Today's Analyst Ratings: Needham Reiterates Buy Rating for RNAC - GuruFocus
Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from Needham & Company LLC - MarketBeat
Cartesian Therapeutics, Inc. 2025 Annual Report – Pipeline, Clinical Trials, Regulatory Approvals, and Competitive Landscape - Minichart
Cantor Fitzgerald Upgrades Cartesian Therapeutics (NASDAQ:RNAC) to Overweight - MarketBeat
Cartesian Therapeutics Inc expected to post a loss of 85 cents a shareEarnings Preview - TradingView
Cartesian Therapeutics posts full year 2025 financial results and issues business update - Traders Union
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Cartesian Therapeutics (NASDAQ:RNAC) Issues Earnings Results, Misses Estimates By $0.56 EPS - MarketBeat
Cartesian Therapeutics 2025 10-K: Revenue $2.8M, Net Loss $130.3M - TradingView
Cartesian backs MG cell therapy trials with $126.9M cash runway into 2027 - Stock Titan
Cartesian Therapeutics (RNAC) to Release Earnings on Thursday - MarketBeat
Published on: 2026-03-02 22:13:30 - baoquankhu1.vn
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Cartesian Therapeutics to present at TD Cowen Health Care Conference in Boston - Traders Union
RNAC Should I Buy - Intellectia AI
Cartesian Therapeutics, Inc. (RNAC): Biotechnology Innovator With A 350% Potential Upside - DirectorsTalk Interviews
Cartesian Therapeutics, Inc. (RNAC) upgraded to buy: What does it mean for the stock? - MSN
Published on: 2026-02-25 09:47:28 - baoquankhu1.vn
Aug Sentiment: What is the earnings history of Cartesian Therapeutics IncWeekly Market Outlook & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Cartesian Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Cell therapy biotech Cartesian Therapeutics plans 3 investor events - Stock Titan
Cartesian Therapeutics: Clinical Pipeline Progress Under Investor Scrutiny () - aktiencheck.de
What drives Cartesian Therapeutics Inc.’s stock priceQuarterly Trade Review & Real-Time Buy Zone Alerts - mfd.ru
Institution Moves: What’s the MACD signal for Cartesian Therapeutics Inc.2025 Buyback Activity & Smart Investment Allocation Insights - mfd.ru
Cartesian Therapeutics, Inc. (RNAC) Investor Outlook: Unpacking a 435.71% Potential Upside in Biotech - DirectorsTalk Interviews
Analyst Upgrade: Is Cartesian Therapeutics Inc attractive for institutional investorsEarnings Recap Report & Low Volatility Stock Recommendations - baoquankhu1.vn
Trading Recap: What are Zenas BioPharma Incs growth leversMarket Trend Review & Verified Entry Point Detection - baoquankhu1.vn
Is Cartesian Therapeutics Inc. stock positioned well for digital economyTrade Volume Summary & Community Verified Trade Signals - mfd.ru
Is Cartesian Therapeutics Inc.’s ROE strong enoughWeekly Gains Report & Risk Managed Investment Entry Signals - mfd.ru
FMR LLC Reduces Stake in Cartesian Therapeutics Inc: A Strategic Portfolio Adjustment - GuruFocus
Is Cartesian Therapeutics Inc. a defensive stockJuly 2025 Setups & Free Low Drawdown Momentum Trade Ideas - mfd.ru
Can JCTC stock outperform in a bear market2025 Geopolitical Influence & Advanced Technical Signal Analysis - baoquankhu1.vn
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cartesian Therapeutics, Inc. (RNAC) Stock Analysis: Exploring a 420% Potential Upside in Biotechnology - DirectorsTalk Interviews
Cartesian Therapeutics (RNAC) Issues New Stock Options to Employ - GuruFocus
Cartesian Therapeutics Announces New Employment Inducement Grants - marketscreener.com
Cartesian Therapeutics (NASDAQ:RNAC) Shares Down 0.6%Here's What Happened - MarketBeat
Will Cartesian Therapeutics (NASDAQ:RNAC) Spend Its Cash Wisely? - simplywall.st
Cartesian Therapeutics, Inc. (RNAC) Stock Analysis: Can a 388.62% Upside Fuel Your Investment Strategy? - DirectorsTalk Interviews
Smart Money: Is Cartesian Therapeutics Inc trading at a discountJuly 2025 Trends & Weekly High Return Stock Forecasts - baoquankhu1.vn
Stop Loss: Will Cartesian Therapeutics Inc outperform during market ralliesJuly 2025 Momentum & Real-Time Volume Spike Alerts - baoquankhu1.vn
Finanzdaten der Cartesian Therapeutics Inc-Aktie (RNAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):